Hansa Biopharma AB, the pioneer in enzyme technology for rare immunological conditions, announced that its first-in-class treatment Idefirix (imlifidase) has been granted early access post marketing authorization (Autorisation… read more.
David Bennet (aged 57 years), the first person to receive a transplanted heart from a gene-edited pig has died, the University of Maryland Medical Centre (UMMC) announced on… read more.
In a retrospective study of adults initiating kidney failure treatment during 2011-2018, disparities in kidney transplantation by race were highest among patients age 22-44 years of age. Within this… read more.
A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping… read more.
A study published in Science Translational Medicine performed at the Latner Thoracic Surgery Research Laboratories and UHN’s Ajmera Transplant Centre has proved that it is possible to convert blood type… read more.
In a first-of-its-kind surgery, a 57-year-old patient with terminal heart disease received a successful transplant of a genetically-modified pig heart and is still doing well three days later…. read more.
Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world’s second leading cause of blindness…. read more.
The increased number of deceased donor liver transplants related to alcoholic hepatitis — up more than 50 percent over predicted numbers — was associated with rising alcohol sales…. read more.
First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.
Immune cells called natural killer cells contribute to organ rejection after transplantation because they miss “self” proteins on donor cells, according to a study appearing in an upcoming… read more.
Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.
Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
